Previous studies revealed that TGF‐β1 could induce MT and enhance the stemness of glioma cells/GSCs during tumour metastasis, which suggested that TGF‐β1 could be used as a molecular target for the clinical treatment of these patients [23]. This evidence concerns the gene TGFB1 and central nervous system cancer.